July 23, 2015

CYTOS
Targeted Immunotherapy

FIRST HALF-YEAR REPORT 2015

as of June 30, 2015

Financial summary

		YTD* 2015	YTD* 2014
Revenue	CHF million	4.5	0.5
Net operating costs	CHF million	(2.3)	(16.5)
Net income/(loss)	CHF million	7.8	(23.4)

		June 30, 2015	December 31, 2014
Cash, cash equivalents & trade and other receivables	CHF million	2.5	17.1
Full-time equivalents	number	3.5	6.6

**YTD = year to date January 1. – June 30.*

Financial Report

Financial Results

Six-month period ended June 30, 2015

Balance sheet

Funds available for financing the Company’s operations amount to CHF 2.5 million as per June 30, 2015, and include cash and cash equivalents, financial assets and trade and other receivables. This is CHF 14.6 million lower than on December 31, 2014 (CHF 17.1 million) and is primarily driven by the repayment of the non-subordinated part of the loan notes to loan notes holders that has been effected on February 10, 2015 (CHF 14.2 million).

Revenue

Revenue comprising deferred income from license fees paid by Novartis of CHF 0.50 million has been recognized in the first six month of 2015, unchanged from the same period in 2014 and in line with past events. Novartis has bought out the collaboration and license contract for CAD106 for a lump-sum payment of CHF 4 million (plus VAT) and Cytos has pre-assigned that payment to the loan note holders as part of the final settlement of all outstanding loan notes. Novartis will not make any further payments under the collaboration and license agreement.

Net operating costs

Net operating costs during the first six months of 2015 amounted to CHF 2.29 million, compared to CHF 16.46 million in the same period of the previous year. Compared to the first half-year 2014, research and development costs decreased by CHF 13.45 million to CHF 0.73 million in the first half-year of 2015 due to the decreased activities after the discontinuation of the Phase 2b clinical study in asthma in the first half-year 2014. General and administrative costs and sales and marketing expenditures combined amounted to CHF 2.83 million (previous year CHF 3.86 million) and do contain costs associated with the restructuring of the debt. Other income in the first half-year of 2015 was CHF 1.27 million which is CHF 0.32 million lower than in the first half- year of 2014 (CHF 1.58 million) and is comprised of proceeds from sub-lease agreements.

Financial income

In the first six month of 2015, financial income was CHF 11.23 million which is significantly higher compared with the corresponding period in the prior year (TCHF 88). The two main elements of this difference are the effects of (i) the mandatory conversion of all convertible bonds into equity (CHF 9.61 million) as well as (ii) a partial waiver of claims by the loan note holders (CHF 1.62 million). Both effects are one-time effects and will no longer occur in the future as all debt has been eliminated.

Financial Results

Six-month period ended June 30, 2015

Financial expenses

Financial expenses were CHF 5.66 million in the first six months of 2015 compared with CHF 7.57 million in the corresponding period in 2014.

Net income

Net income was CHF 7.77 million in the first half-year of 2015, compared to a net loss of CHF 23.44 million in the same period in 2014. This significant decrease is mostly based on one-time effects related to the elimination of debt as described above, as well as revenue from the amendment (buy-out) of the collaboration and license agreement for CAD106 by Novartis. All these effects are one-time effects and will not occur again. Furthermore, the on-going operating costs have been significantly reduced due to decreased operating activities.

Cash burn

The gross cash burn for operating activities, as calculated on the cash flow statement, was CHF 0.41 million on average per month during the first six months of 2015, compared to CHF 3.31 million on average per month in the first half-year of 2014.

Cytos Biotechnology Ltd and its subsidiary

Consolidated Balance Sheets as of

in TCHF	Note	June 30, 2015	December 31, 2014
Non-current assets:			
Property and equipment, net	9	–	–
Investment in associates		80	80
Total non-current assets		**80**	**80**
Current assets:			
Pension assets		–	83
Prepayments and other assets		338	413
Trade and other receivables		305	120
Cash and cash equivalents	8	2,163	16,935
Total current assets		**2,806**	**17,551**
Total assets		**2,886**	**17,631**
Shareholders' equity:			
Share capital	4	3,240	3,053
Legal reserves		2	2
Additional paid-in capital		295,843	266,360
Convertible Bond/loan notes: equity component		–	9,830
Treasury shares		(210)	(210)
Accumulated deficit		(297,552)	(305,255)
Total shareholders' equity		**1,323**	**(26,220)**
Non-current liabilities:			
Convertible Bond/loan notes: liability component		–	–
Convertible Bond/loan notes: accrued interest		–	–
Pension liabilities		1	–
Provisions		–	–
Total non-current liabilities		**1**	**–**
Current liabilities:			
Trade accounts payable		107	152
Other current liabilities		459	110
Accrued expenses		677	424
Convertible Bond/loan notes: liability component	10	–	37,592
Convertible Bond/loan notes: accrued interest	10	–	4,931
Deferred income		319	642
Provisions		–	–
Total current liabilities		**1,562**	**43,851**
Total shareholders' equity and liabilities		**2,886**	**17,631**

See accompanying notes, which are an integral part of these condensed consolidated interim financial statements.

Cytos Biotechnology Ltd and it subsidiary

Consolidated Income Statements

in TCHF	Note	Six months ended June 30, 2015	Six months ended June 30, 2014
Revenue	5	4,500	500
Revenue		**4,500**	**500**
Research and development		(729)	(14,183)
Sales and marketing		(14)	(148)
General and administrative		(2,819)	(3,716)
Other income		1,268	1,583
Net operating costs		**(2,294)**	**(16,464)**
Operating income/(loss)		**2,206**	**(15,964)**
Financial income		11,229	88
Financial expense		(5,663)	(7,568)
Income/(loss) before deferred tax		**7,772**	**(23,444)**
Tax income		–	–
Net income/(loss)		**7,772**	**(23,444)**

Consolidated Statements of Comprehensive Income

in TCHF (except for share information)	Note	Six months ended June 30, 2015	Six months ended June 30, 2014
Net income/(loss)		7,772	(23,444)
Items that will not be reclassified to profit or loss:			
Remeasurement of pension liabilities due to adoption of IAS19R		(68)	(25)
Other comprehensive loss		**(68)**	**(25)**
Total comprehensive income/(loss)		**7,704**	**(23,469)**

See accompanying notes that are an integral part of these condensed consolidated interim financial statements.

Cytos Biotechnology Ltd and its subsidiary

Consolidated Condensed Statements of Cash Flows in TCHF	Note	Six months ended June 30, 2015	Six months ended June 30, 2014
Cash flow from operating activities:			
Net income/(loss)		7,772	(23,444)
Depreciation and amortization		–	20
Impairment of assets		–	93
Share-based compensation	7	749	885
Other cash flow items		(11,118)	6,982
Changes in assets and liabilities		158	(6,405)
Net cash used in operating activities		**(2,439)**	**(21,869)**
Net cash provided by /(used in) investing activities		**–**	**188**
Net cash provided by /(used in) financing activities		**(12,314)**	**190**
Net decrease in cash and cash equivalents		(14,753)	(21,491)
Net effect of currency translation on cash		(19)	26
Cash and cash equivalents, beginning of period		16,935	39,847
Cash and cash equivalents, end of period		**2,163**	**18,382**

See accompanying notes that are an integral part of these condensed consolidated interim financial statements.

Cytos Biotechnology Ltd and its subsidiary

Consolidated Statements of Change in Shareholders' Equity

in TCHF (except for share information)	Number of shares	Share capital	Legal reserves	Additional paid-in capital	Convertible Bond/loan notes: equity component	Treasury shares	Accumulated deficit	Cumulative translation adjustments	Total
January 1, 2014	**30,525,276**	**3,053**	**2**	**262,428**	**9,830**	**(216)**	**(270,658)**	**(209)**	**4,230**
Total comprehensive loss	–	–	–	–	–	–	(23,469)	–	(23,469)
Issuance of share capital									
from Treasury shares	55,520	6	–	184	–	–	–	–	190
Use of Treasury Shares	(55,520)	(6)	–	–	–	6	–	–	–
Share-based compensation	–	–	–	885	–	–	–	–	885
June 30, 2014	**30,525,276**	**3,053**	**2**	**263,497**	**9,830**	**(210)**	**(294,127)**	**(209)**	**(18,164)**
January 1, 2015	**30,525,276**	**3,053**	**2**	**266,360**	**9,830**	**(210)**	**(305,044)**	**(211)**	**(26,220)**
Total comprehensive income	–	–	–	–	–	–	7,704	(1)	7,703
Nominal value reduction of shares	–	(2,137)	–	2,137	–	–	–	–	–
Issuance of share capital	77,490,000	2,324	–	17,048	–	–	–	–	19,372
Reclass equity component	–	–	–	9,830	(9,830)	–	–	–	–
Share capital issuance costs	–	–	–	(281)	–	–	–	–	(281)
Share-based compensation	–	–	–	749	–	–	–	–	749
June 30, 2015	**108,015,276**	**3,240**	**2**	**295,843**	**–**	**(210)**	**(297,340)**	**(212)**	**1,323**

See accompanying notes that are an integral part of these condensed consolidated interim financial statements.

Notes

1. Organization

Cytos is a public biopharmaceutical company domiciled in Schlieren, Switzerland and is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Cytos operational activities have been substantially reduced as explained in note 2 below.

As of June 30, 2015, Cytos has four employees which are primarily looking for suitable strategic opportunities such as reverse merger candidates and/or programs with the aim to revitalize the Company which would put it again on a sustainable path.

The consolidated condensed interim financial statements have been approved for issuance by the Audit Committee on July 23, 2015.

2. Basis of preparation

These consolidated condensed interim financial statements have been prepared in accordance with IAS 34 “Interim Financial Reporting” on a going concern basis.

Following a major set-back in April 2014 in a phase IIb clinical trial with its lead assets, CYT003, Cytos conducted a major wind-down of its operational activities throughout 2014 and the first half of 2015 including but not limited to (i) stopping the clinical trial, (ii) reducing head count down to four employees as of June 30, 2015, (ii) eliminate all financial debt including the convertible bonds (originally due February 20, 2015) and the convertible loan notes (originally due February 10, 2015) and (iv) minimize the ongoing operating costs such as rent, etc. to the maximum extent possible including but not limited to further sub-letting premises which has a positive cash effect. Furthermore, Cytos has been pursuing activities to monetize on pre-clinical programs and technology assets. Given the outcome of these measures and taking into consideration that Cytos has enough financial means to sustain operations for the next twelve months, the Board of Directors and the management believe that it is appropriate to prepare these financial statements on a going concern basis.

The Company is and remains to be subject to various risks and uncertainties, including, but not limited to the time of achieving sustainable profitability and the uncertainty of the discovery, development, and commercialization of product candidates, which includes uncertainty of the outcome of clinical trials and significant regulatory approval requirements.

The Company has certain product candidates in its portfolio. However, most of these products are licensed to third parties and it is not likely at this point in time, that these products will contribute in a significant manner to the financial situation of the Company within the next year or two. Therefore, Cytos is and will remain for the foreseeable future dependent on equity financing to sustain operations.

The consolidated condensed interim financial statement should be read in conjunction with the annual financial statements for the year ended December 31, 2014. For better readability, the amounts in the Group’s financial statements and notes are presented in thousands Swiss francs (TCHF) unless stated otherwise.

3. Seasonality

Operating costs and revenue are not exposed to substantial seasonal variations. However, revenue from biotech companies may vary significantly throughout the year, since revenue is often linked to up-front payments, milestone and license payments, as well as payments for delivery of drug substances, which occur sporadically.

4. Shareholders' equity

Options

No options were issued or exercised in the first six months of 2015. In the first half-year 2014, 55,520 options have been exercised with an exercise price of CHF 3.41. The Shares needed for this exercise were taken from the Treasury Shares (TCHF 5.55). From the exercise of these options a cash inflow of TCHF 189.18 has been accounted for (agio: TCHF 183.77).

5. Segment and geographic information

Business segment

The Group operates in one segment solely, focusing on the development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The Group's Executive Board reviews the profit or loss of the Group on an aggregated basis. The operations of the Group are managed as a single operating segment. The Group derives its research and collaboration revenues from research and development collaborations with third parties.

Geographical segments

All revenue are generated in Switzerland. All operating costs, including research and development, sales and marketing, general and administrative, other operating income and expenses arise in Switzerland as well.

The Group's geographic information is as follows in TCHF:

Additional information:	June 30, 2015	December 31, 2014
Total non-current assets*	80	80
Total liabilities	1,563	43,851

	Six months ended June 30, 2015	Six months ended June 30, 2014
Capital expenditure for property and equipment	–	20
Depreciation and amortization	–	20
Impairment of property and equipment	–	93

**No adjustments to non-current assets are required as in line with definition of IFRS 8.*

Analysis of revenue by category:

in TCHF	Six months ended June 30, 2015	Six months ended June 30, 2014
Revenue from Novartis royalties and licenses*	4,500	500
Total	**4,500**	**500**

**including revenue from the buy-out of CAD106 by Novartis (TCHF 4,000).*

6. Share option plans

The Group regularly grants share options to the members of the Board of Directors, the members of the Executive Board, as well as to the employees and consultants of the Company. The fair value of the options is determined at the grant date, based on the market price, by using the Black-Scholes model.

The share options under the stock option plan 2014 ("SOP 2014") were granted as per December 20, 2013. In the first half year 2014 and 2015, no further share options were granted.

The expenses for the share-based compensation in relation to the granted share options amounted to TCHF 749 for the first six months of 2015 (TCHF 885 for the first six months of 2014).

7. Cash, cash equivalents and financial assets

Due to the current low interest rate of fixed deposits, Cytos has not made any investments in financial assets in the first six months of 2014 and 2015.

8. Property and equipment

No investment was made in the first semester of 2015. In the first six months of 2014, the Group invested TCHF 20 into IT equipment. The Group owns no properties.

9. Current-/non-current liabilities

Original Convertible Bond (see next page "Restructured Convertible Bond")

In February 2007, the Company issued 2.875% p.a. convertible bonds ("Convertible Bond") with a nominal value of CHF 70.00 million, which were listed on the SIX Swiss Exchange under the symbol CYT07 (security number 2 906 073). The Convertible Bond was initially due for repayment on February 20, 2012, and was convertible into the Company's shares at a conversion price of CHF 175.

The values of the liability component and the equity conversion component were determined upon issuing the Convertible Bond.

The fair value of the liability component, included in "non-current liabilities", was calculated using a market interest rate for an equivalent non-convertible bond. The residual amount, representing the value of the equity conversion option, is included in shareholders' equity.

Transaction costs associated with the issuance have been allocated proportionately to the liability and equity components.

The "original" Convertible Bond recognized in the balance sheet is calculated as follows:	TCHF
Nominal value of the Convertible Bond issued in February 2007	70,000
Equity component	(11,788)
Transaction costs allocated to liability component	(1,811)
Liability component on initial recognition	**56,401**
Interest expense	19,111
Partial repurchase of convertible bonds	(38,601)
Gain on partial repurchase of liability component of convertible bonds	(15,425)
Partial repurchase of equity component	2,385
Interest paid	(6,703)
Liability component as per February 20, 2012	**17,168**
Thereof interest as per February 20, 2012, due on February 20, 2015	1,033

Due to the restructuring of the Convertible Bond, the accrued interest as per February 20, 2012, of TCHF 1,033 was due on February 20, 2015.

Restructured Convertible Bond

The Convertible Bond which was issued in 2007 was due for repayment on February 20, 2012. However, because Cytos did not have enough financial means to fully repay the Convertible Bond at maturity, it proposed a bond restructuring to the bondholders on November 10, 2011 (“first restructuring”). In summary, Cytos proposed to repay half of the outstanding nominal value at par and to postpone the repayment for the remaining half as well as to defer the payment of any interest to February 20, 2015. The repayment was set to be at 150% of par value. In addition, the coupon had been increased from 2.875% p.a. to 5.75% p.a. Furthermore the conversion price had been reduced to CHF 7.71 (this price was reduced later on due to the anti-dilution clause).

The value of the liability component of the restructured Convertible Bond was determined based on a discount rate of 47.86%. The remaining value has been allocated to the equity component.

As Cytos still did not have the financial means to repay the restructured convertible bonds on February 20, 2015, it proposed another restructuring to the bondholders on January 26, 2015 (“second restructuring”). Along this proposal, which became final and legally binding on May 4, 2015, all outstanding convertible bonds were converted into equity at a conversion price per share of CHF 0.25 plus an incentive fee (CHF 25.00 per bond), i.e. each convertible bond of nominal CHF 2’500 was converted into 10’000 Cytos shares. In total, convertible bonds with a nominal value of CHF 19’372’500 were exchanged into 77.49 million shares.

In January 2015, Cytos exchanged a nominal of CHF 4 million convertible bonds (out of treasury) against claims of CHF 2 million with a convertible loan note holder. Furthermore, Cytos sold a nominal of CHF 2’205’000 convertible bonds (out of treasury) to a third party for 56%, i.e. CHF 1’234’800.

The restructured Convertible Bond recognized in the balance sheet is calculated as follows:	**HY/2015**	**HY/2014**
	TCHF	TCHF
Nominal value of the restructured Convertible Bond	16,135	16,135
Adjustment to fair value as per February 20, 2012*	(7,100)	(7,100)
Equity component	(688)	(688)
Transaction costs allocated to liability component	(115)	(115)
Liability component on initial recognition at February 20, 2012	**8,232**	**8,232**
Interest expense	13,033	9,227
Partial repurchase of convertible bonds	(1,880)	(1,880)
Loss on partial repurchase of liability component of convertible bonds	240	240
Partial repurchase of equity component	127	127
Sales to third parties	1,234	–
Exchange Bonds to loan note swap	2,000	–
Liability component before settlement as per May, 6 2015	**22,986**	**15,946**
Accrued interest	3,028	2,170
Bond conversion into equity, share capital	(2,324)	
Bond conversion into equity, additional paid-in capital	(17,048)	
Gain on restructuring**	(6,642)	

**The adjustment of fair value has been recorded as financial income in 2012.*

***The gain on restructuring has been recognized as "financial income"* (TCHF 9,612) and as "financial expense" (TCHF 2,970).

The total interest expense amounted to CHF 1.05 million and has been recognized as “financial expense” for the period from January 1 to February 20, of 2015 (for the first six months of 2014: CHF 3.52 million).

First tranche of the Convertible loan notes

Four investors granted Cytos Biotechnology Ltd convertible loan notes, payable in two equal tranches with a total amount of CHF 13.25 million. The convertible loan notes (capital and interest) could have been converted into shares of the Company, whereby the conversion price was CHF 2.13 for the capital. The first tranche of CHF 6.625 million was due for payment upon completion of the capital increase and was paid on May 15, 2012. For the second tranche of the convertible loan notes of CHF 6.625 million we refer to the next page, “second tranche of the convertible loan notes”. The convertible loan notes carried an interest rate of 9% p.a. and were due for repayment at 150% of the nominal value on February 10, 2015.

The value of the liability component of the first tranche of the convertible loan notes was determined based on a discount rate of 61.19%. The remaining value has been allocated to the equity component.

The convertible loan notes recognized in the balance sheet are calculated as follows:	**HY/2015** TCHF	**HY/2014** TCHF
Nominal value of the convertible loan notes issued in May 2012*	6,625	6,625
Equity component	(3,572)	(3,572)
Transaction costs allocated to liability component	(102)	(102)
Liability component on initial recognition on May 15, 2012	**2,951**	**2,951**
Exchange Bonds to loan note swap	(1,000)	–
Interest expense	8,620	4,687
Liability component as per February 10, 2015	**10,571**	**7,638**
Repayments of non-subordinated portion of loan note	(7,581)	–
Cancellation of debt as of May 11, 2015**	(2,990)	–
Accrued interest (deferred until February 10, 2015)	–	1,096

**Granted by:*
– venBio Global Strategic Fund L.P., Grand Cayman (Cayman Islands)
– Amgen Investments Ltd., Hamilton (Bermuda)
– Abingworth Bioventures V L.P., London (UK)
– Aisling Capital III L.P., New York (USA)
***The elimination has been recognized as "financial income"*
(Total TCHF 5'977, including the second tranche of the loan note)

The total interest expense amounted to CHF 0.74 million and has been recognized for the period from January 1 to February 10, of 2015 as “financial expense” (for the first six months of 2014: CHF 2.06 million).

Second tranche of the convertible loan notes

Upon completion of enrollment in the ongoing Phase 2b clinical trial with CYT003 in allergic asthma, the Company called the second tranche of CHF 6.625 million on October 21, 2013. The second tranche of the convertible loan notes of CHF 6.625 million was paid in four different installments between October 29, 2013 and December 10, 2013. The convertible loan notes carried an interest rate of 9% p.a. and were due for repayment at 150% of the nominal value on February 10, 2015.

The value of the liability component of the second tranche of the convertible loan notes was determined based on a discount rate of 61.19%. The remaining value has been allocated to the equity component.

The convertible loan notes recognized in the balance sheet are calculated as follows:	**HY/2015** TCHF	**HY/2014** TCHF
Nominal value of the convertible loan notes issued in October and December 2013*	6,625	6,625
Equity component	(711)	(711
Liability component on initial recognition in October and December 2013	**5,914**	**5,914**
Exchange Bonds to loan note swap	(1,000)	–
Interest expense	4,730	1,831
Liability component as per February 10, 2015	**9,644**	**7,745**
Repayments of non-subordinated portion of loan note	**(6,657)**	–
Cancellation of debt as of May 11, 2015**	(2,987)	–
Accrued interest (deferred until February 10, 2015)	–	323

**Granted by:*
- venBio Global Strategic Fund L.P., Grand Cayman (Cayman Islands)
- Amgen Investments Ltd., Hamilton (Bermuda)
- Abingworth Bioventures V L.P., London (UK)
- Aisling Capital III L.P., New York, NY (USA)
***The elimination has been recognized as "financial income"*
(Total TCHF 5'977, including the first tranche of the loan note)

The total interest expense amounted to CHF 0.68 million and has been recognized for the period from January 1 to February 10, of 2015 as “financial expense” (for the first six months of 2014: CHF 1.87 million).

Summary for both tranches of the convertible loan notes

As of May 2, 2014 a total amount of CHF 7.00 million was subordinated. This amount includes CHF 6.625 million of the principle amount of the first and second tranche of the convertible loan note and accrued interests in the amount of TCHF 375. In addition to this, any interest due for the convertible loan notes accruing after April 14, 2014 was subordinated as well.

At maturity, i.e. on February 10, 2015, CHF 14’238’125 (which is the non-subordinated part of the loan notes) was repaid. With effect as of May 4, 2015, a settlement with the convertible loan note holders was reached eliminating all claims from the convertible loan notes immediately after the conversion of the bonds into equity. In exchange, Cytos will make a final payment of around CHF 4.4 million to the loan notes holders once it has received the CHF 4 million from Novartis for the buy-out of CAD106 as well as some payments from OnCore (now: Tekmira).

12. Events after balance sheet date

The closing took place of the license agreement with Tekmira under which certain payments are to be made. The closing of the amendment of the collaboration and license agreement (buy-out) by Novartis triggered a payment of CHF 4 million (plus VAT). In conjunction with the settlement with loan note holders, receivables in the amount of CHF 4,359,962.50 were assigned to them and, following the receipt of the above payment, a sum in the same amount was paid to the loan note holders.

With effect as of July 1, 2015, a total of 5.4 million options were granted with a duration of five years, a regular vesting of four years, a full vesting upon change of control and a strike price of CHF 0.60 (the closing price of the Cytos share on July 1, 2015 was CHF 0.55).

Disclaimer

Cautionary Statement regarding Forward-looking Statements:
Certain statements in this quarterly report, including but not limited to statements, estimates and projections of future trends and of the anticipated future performance of Cytos Biotechnology Ltd and its subsidiary (together “the Group”), constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievement of the Group, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. The forward-looking statements are based on the Group’s current beliefs and assumptions regarding a large number of factors affecting its business. Such beliefs and assumptions are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Group. There can be no assurance that: (i) the Group has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the publicly available information with respect to these factors on which the Group’s analysis is based is complete or accurate, (iii) the Group’s analysis is correct or (iv) the Group’s strategy, which is based in part on this analysis, will be successful. Factors which affect the Group’s business include, but are not limited to, (i) general market, governmental and regulatory trends, (ii) competitive pressures, (iii) technological developments, (iv) effectiveness and safety of the Group’s technology and therapeutics, (v) uncertainty regarding outcome of clinical trials and regulatory approval process, (vi) management changes, (vii) changes in the market in which the Group operates, and (viii) changes in the financial position or creditworthiness of the Group’s customers and partners.

Stock exchange listings at SIX Swiss Exchange

Registered shares: Swiss Security No. 1 102 521, SIX:CYTN

Share register

Aktienregister Cytos Biotechnology Ltd
c/o Nimbus AG
Postfach
CH-8866 Ziegelbrücke (Switzerland)

Capital structure

Number of registered shares (nominal value CHF 0.03)	108,015,276
Conditional capital	CHF 3,240,458.32
Authorized capital	CHF 3,240,458.32
Free float	100%

Contact

Harry Welten, MBA
Chief Financial Officer
Tel.: +41 44 733 46 46
E-mail: harry.welten@cytos.com

Cytos is a public biopharmaceutical company domiciled in Schlieren, Switzerland and is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Cytos was founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich.